Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Selumetinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 known ✓ | Q02750 | 20/20 | 1.00 |
| ▸ | MAP2K2 known ✓ | P36507 | 3/20 | 1.00 |
| ▸ | SMC2 | O95347 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 1.00 |
| ▸ | SMC1A | Q14683 | 1/20 | 1.00 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 1.00 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 1.00 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.84 |
| ▸ | NQO2 | P16083 | 1/20 | 0.84 |
| ▸ | BRAF | P15056 | 5/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Selumetinib SCHEMBL29353582 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| Selumetinib SCHEMBL29555068 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| Selumetinib SCHEMBL2354340 | 0.97 | MAP2K1 (0.94) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| Selumetinib SCHEMBL29744701 | 0.97 | MAP2K1 (0.94) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL4546029 | 0.95 | MAP2K1 (0.91) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| Selumetinib SCHEMBL30487255 | 0.94 | MAP2K1 (0.89) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| Selumetinib SCHEMBL30487260 | 0.93 | MAP2K1 (0.88) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL21501424 | 0.93 | MAP2K1 (0.87) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL4546010 | 0.93 | MAP2K1 (0.87) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL19141378 | 0.92 | MAP2K1 (0.86) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10031 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747285-A1 | MONOCLONAL ANTIBODIES AGAINST PCDH7 FOR LUNG CANCER THERAPY | The Board of Regents of the University of Texas System (US) | 2026-05-27 | — | — | EP | claimed |
| CN-122075716-A | Medicine for treating tumor by combining recombinant oncolytic virus and small-molecule anticancer medicine | — | 2026-05-26 | — | — | CN | claimed |
| US-12636376-B2 | Methods and compositions for use of growth factor antibodies in combination with non-tyrosine targeting kinase inhibitors | IN3BIO LTD. (BM) | 2026-05-26 | — | — | US | claimed |
| CN-122070932-A | Application of combination of decitabine and anti-HER 2 antibody in preparation of medicines for treating tumors | 上海交通大学 | 2026-05-22 | — | — | CN | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| US-20260130856-A1 | LIPOSOME COMPOSITIONS FOR DELIVERY OF COMPOUNDS AND METHODS THEREOF | NANOTECH PHARMA INC (US) | 2026-05-14 | — | — | US | claimed |
| EP-4741395-A1 | NOVEL COMPOUND SENSITIVE TO NITROGEN MONOXIDE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Omniamed Co. Ltd (KR) | 2026-05-13 | — | — | EP | claimed |
| US-20260115209-A1 | COMBINATION THERAPY INCLUDING COX-2 INHIBITOR FOR THE TREATMENT OF CANCER | UNIV CALIFORNIA (US) | 2026-04-30 | — | — | US | claimed |
| WO-2026090321-A1 | TREATMENT OF CANCER WITH A KRAS INHIBITOR | ALTEROME THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| WO-2026090174-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS AND METHODS FOR THE SYNTHESIS AND USE THEREOF | BRYET US, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| WO-2015169884-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ITCH | WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER (DE) | 2015-11-12 | — | — | WO | claimed |
| US-20150141380-A1 | INHIBITORS OF ERK FOR DEVELOPMENTAL DISORDERS OF NEURONAL CONNECTIVITY | CASE WESTERN RESERVE UNIVERSITY (US) | 2015-05-21 | — | — | US | claimed |
| WO-2015002729-A2 | CELL STABILIZATION | BIOMATRICA, INC. (US) | 2015-01-08 | — | — | WO | claimed |
| US-20140200260-A1 | METHODS FOR DETERMINING AND INHIBITING RHEUMATOID ARTHRITIS ASSOCIATED WITH THE BRAF ONCOGENE IN A SUBJECT | THE UNITED STATES OF AMERICA AS REPRESENTED BY | 2014-07-17 | — | — | US | claimed |
| EP-2600862-A2 | INHIBITORS OF ERK FOR DEVELOPMENTAL DISORDERS OF NEURONAL CONNECTIVITY | Case Western Reserve University (US) | 2013-06-12 | — | — | EP | claimed |
| WO-2012019113-A2 | INHIBITORS OF ERK FOR DEVELOPMENTAL DISORDERS OF NEURONAL CONNECTIVITY | CASE WESTERN RESERVE UNIVERSITY (US) | 2012-02-09 | — | — | WO | claimed |
| WO-2011095807-A1 | COMBINATIONS OF MEK AND HH INHIBITORS | ASTRAZENECA AB (SE) | 2011-08-11 | — | — | WO | claimed |
| US-20110158971-A1 | COMPOSITIONS COMPRISING N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-06-30 | — | — | US | claimed |
| JP-2011506420-A | — | — | 2011-03-03 | — | — | JP | claimed |
| EP-2271321-A1 | PHARMACEUTICAL COMPOSITION 271 | AstraZeneca AB (SE) | 2011-01-12 | — | — | EP | claimed |